Yaupon Therapeutics raises $14.4 million in Series D financing
Yaupon Therapeutics, a privately held pharmaceutical company, has raised $14.4 million through a Series D private placement of preferred stock. The new round includes prior investors Vivo Ventures, Palo Alto Investors and Burrill & Company, plus new investor, Aperture Venture Partners.
Yaupon recently submitted a New Drug Application (NDA) to the FDA for a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).
"This financing provides us with the necessary capital to take us through the NDA regulatory review process, while preparing for commercialization either alone or with an industry partner," said Yaupon chairman and CEO Steve Tullman.